The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

This phase IV, multicenter, prospective, open-label tolerability and safety monitoring study will enroll a select cohort of 500 multiple sclerosis patients receiving commercially available Novantrone®. The patients will be assessed every 3 months during treatment followed by annual assessment for a total of five (5) years.

The select cohort of MS patients enrolled will have secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting disease (i.e., patients whose neurological status is significantly abnormal between relapses).

The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

Inclusion Criteria:

• To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria:
• Platelet count >100,000 cells/µL
• Granulocyte count > 2000 cells/µL
• Age 18-65 years
• Negative pregnancy test for female patients who are biologically capable of becoming pregnant, even if they are taking birth control
• For patients of reproductive age, agreement to practice effective contraception throughout the study and for 6 months following the last administration of Novantrone®
• Signed Inform Consent.

Exclusion Criteria:

• To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
• Presence of cardiac risk factors:
• History of congestive heart failure
• LVEF < 50% determined by echocardiography or MUGA
• Previous treatment with Novantrone®, other anthracenediones, or anthracyclines
• Prior mediastinal radiotherapy or total lymphoidal irradiation
• AST, ALT, bilirubin > 2x upper limits of normal
• Severe untreated infection (including current urinary tract infection)
• Nursing or pregnant women)

Male and female patients with a clinically definite or laboratory supported diagnosis of MS and having secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting disease (i.e., patients whose neurologic status is significantly abnormal between relapses). Patients with primary progressive disease will not be included in this study.

Up to 5 years. Combined serious adverse events are displayed for both the Treatment Phase and Annual Follow-Up Phase

Only serious adverse events were collected in this study